Acadia Pharmaceuticals
ACAD
310 hedge funds and large institutions have $3.66B invested in Acadia Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 101 increasing their positions, 123 reducing their positions, and 54 closing their positions.
154% more call options, than puts
Call options by funds: $19.9M | Put options by funds: $7.8M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $2.87B → $3.66B (+$791M)
2.24% less ownership
Funds ownership: 103.71% → 101.47% (-2.2%)
3% less funds holding
Funds holding: 319 → 310 (-9)
13% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 54
18% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 123
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$50.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$30.5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$21.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$13.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$36.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.4M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$22.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 5 |
Two Sigma Advisers
New York
|
-$14.4M |
ACAD Hedge Fund Activity: Q2 2025 in Review
310 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2025, worth a combined $3.66B — up 28% from $2.87B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of ACAD and 47 opened new positions — a net loss of 7 holders — while 123 trimmed existing stakes and 101 added.
The largest buyer was Citadel Advisors, adding an estimated $50.5M. The largest seller was Assenagon Asset Management, cutting an estimated $36.3M.
- 310 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2025, down from 319 in Q1 2025.
- Funds reported $3.66B of Acadia Pharmaceuticals stock for Q2 2025, up 28% quarter-over-quarter.
- 47 funds opened new Acadia Pharmaceuticals positions in Q2 2025 and 54 closed out, a net change of -7 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $50.5M added.
- The largest Acadia Pharmaceuticals seller in Q2 2025 was Assenagon Asset Management, an estimated $36.3M sold.
Based on aggregated 13F filings for Q2 2025.